AU2014350334B2 - Hydrobromide salt ofN-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N'-(3-fluoro-2-methylphenyl)urea - Google Patents

Hydrobromide salt ofN-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N'-(3-fluoro-2-methylphenyl)urea Download PDF

Info

Publication number
AU2014350334B2
AU2014350334B2 AU2014350334A AU2014350334A AU2014350334B2 AU 2014350334 B2 AU2014350334 B2 AU 2014350334B2 AU 2014350334 A AU2014350334 A AU 2014350334A AU 2014350334 A AU2014350334 A AU 2014350334A AU 2014350334 B2 AU2014350334 B2 AU 2014350334B2
Authority
AU
Australia
Prior art keywords
disease
compound
condition
treating
indicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014350334A
Other languages
English (en)
Other versions
AU2014350334A1 (en
Inventor
Francis Dominic Sanderson
Sarah Mary VALLANCE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of AU2014350334A1 publication Critical patent/AU2014350334A1/en
Application granted granted Critical
Publication of AU2014350334B2 publication Critical patent/AU2014350334B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014350334A 2013-11-13 2014-11-11 Hydrobromide salt ofN-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N'-(3-fluoro-2-methylphenyl)urea Ceased AU2014350334B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1320021.7 2013-11-13
GBGB1320021.7A GB201320021D0 (en) 2013-11-13 2013-11-13 Novel Compounds
PCT/EP2014/074222 WO2015071235A1 (en) 2013-11-13 2014-11-11 Hydrobromide salt ofn-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea

Publications (2)

Publication Number Publication Date
AU2014350334A1 AU2014350334A1 (en) 2016-06-02
AU2014350334B2 true AU2014350334B2 (en) 2017-08-10

Family

ID=49818555

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014350334A Ceased AU2014350334B2 (en) 2013-11-13 2014-11-11 Hydrobromide salt ofN-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N'-(3-fluoro-2-methylphenyl)urea

Country Status (24)

Country Link
US (3) US9809540B2 (enExample)
EP (1) EP3068763B1 (enExample)
JP (1) JP6401265B2 (enExample)
KR (1) KR20160083950A (enExample)
CN (1) CN105683162A (enExample)
AU (1) AU2014350334B2 (enExample)
BR (1) BR112016010409A8 (enExample)
CA (1) CA2929907A1 (enExample)
CY (1) CY1121581T1 (enExample)
DK (1) DK3068763T3 (enExample)
ES (1) ES2714721T3 (enExample)
GB (1) GB201320021D0 (enExample)
HR (1) HRP20190449T1 (enExample)
HU (1) HUE041873T2 (enExample)
LT (1) LT3068763T (enExample)
ME (1) ME03328B (enExample)
PL (1) PL3068763T3 (enExample)
PT (1) PT3068763T (enExample)
RS (1) RS58382B1 (enExample)
RU (1) RU2685408C1 (enExample)
SI (1) SI3068763T1 (enExample)
SM (1) SMT201900156T1 (enExample)
TR (1) TR201902981T4 (enExample)
WO (1) WO2015071235A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107072976A (zh) * 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
BR112018011138A2 (pt) * 2015-11-30 2018-11-21 Glaxosmithkline Intellectual Property (No. formulações para administração intravenosa
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009992B1 (en) * 2006-04-21 2012-06-27 GlaxoSmithKline LLC Il-8 receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D1 : WO 2007/124424 A1 *
D2 : STEPHEN M BERGE ET AL: "Pharmaceutical salts", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 66, no. 1, 1 January 1977, pages 1-19 *

Also Published As

Publication number Publication date
CY1121581T1 (el) 2020-05-29
HUE041873T2 (hu) 2019-05-28
US10604485B2 (en) 2020-03-31
LT3068763T (lt) 2019-03-12
JP6401265B2 (ja) 2018-10-10
EP3068763A1 (en) 2016-09-21
JP2016537344A (ja) 2016-12-01
US20190112269A1 (en) 2019-04-18
PL3068763T3 (pl) 2019-05-31
RU2685408C1 (ru) 2019-04-18
ES2714721T3 (es) 2019-05-29
TR201902981T4 (tr) 2019-03-21
US20160264525A1 (en) 2016-09-15
PT3068763T (pt) 2019-03-20
CA2929907A1 (en) 2015-05-21
ME03328B (me) 2019-10-20
RS58382B1 (sr) 2019-04-30
CN105683162A (zh) 2016-06-15
AU2014350334A1 (en) 2016-06-02
EP3068763B1 (en) 2018-12-19
SMT201900156T1 (it) 2019-05-10
WO2015071235A1 (en) 2015-05-21
BR112016010409A8 (pt) 2020-04-22
SI3068763T1 (sl) 2019-04-30
RU2016116955A (ru) 2017-12-19
US20180079722A1 (en) 2018-03-22
HRP20190449T1 (hr) 2019-04-19
DK3068763T3 (en) 2019-03-18
KR20160083950A (ko) 2016-07-12
GB201320021D0 (en) 2013-12-25
US9809540B2 (en) 2017-11-07

Similar Documents

Publication Publication Date Title
CA2915561C (en) Novel substituted bicyclic compounds as bromodomain inhibitors
CA3183081A1 (en) Combination therapy for treatment of cancer
JP7660604B2 (ja) ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の大規模調製のためのプロセスおよび中間体、ならびに２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミド酢酸塩の調製
CN105934255A (zh) 用于治疗癌症的包括mdm2抑制剂和一种或多种另外的药物活性剂的组合疗法
US10604485B2 (en) Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N′-(3-Fluoro-2-methylphenyl)urea
TR201802206T4 (tr) Amorf (5-Floro-2-metil-3-kinolin-2-ilmetil-indol-1-il)-asetik asit.
CA3075705A1 (en) Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
TW202345799A (zh) Ｔｙｋ２抑制劑及其用途
CA3163930A1 (en) Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms
WO2017106872A1 (en) Alkynyl dihydroquinoline sulfonamide compounds
CN111620815B (zh) 手性氯喹、羟氯喹和其衍生物及其制备方法与用途
JPH09511483A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノリン化合物
CA3148939A1 (en) Compositions and methods for the treatment of estrogen-dependent disorders
CN114080225A (zh) 治疗癌症的方法
CN103965179A (zh) 作为m3毒蕈碱性受体拮抗剂的吡咯烷鎓衍生物的多晶型物、其制备方法及药物组合物
HUE028761T2 (en) Crystalline form of a succinate salt
US6372763B1 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
JP2025507623A (ja) （ｓ）－１－（（２’，６－ビス（ジフルオロメチル）－［２，４’－ビピリジン］－５－イル）オキシ）－２，４－ジメチルペンタン－２－アミン及びその塩の固体形態
JP2011246478A (ja) テルカゲパントカリウムの固形投与製剤
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
TW201625253A (zh) 包含ｐｇｄ２拮抗劑之伴隨過敏性疾病之症狀之治療用醫藥
RU2161967C2 (ru) Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора
AU2006291059A1 (en) Salicylate and gentisate salts of a piperazine compound
CN108658843A (zh) 乙酰苄胺哌啶酰胺类衍生物及其作为脑神经保护剂的应用
WO2022109292A1 (en) Methods and materials for inhibiting cb1 activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired